A finalized leap-frog guidance on technical considerations for 3D printing isn't a major change from the draft version, but it does clarify FDA's expectation for removing manufacturing material residue in additive manufacturing processes.
FDA issued the draft guidance in May 2016 as part of an effort to get ahead of the inevitable boom in additive manufacturing to support manufacturing of devices, make more personalized medical technology and create 3D models that surgeons can use to enhance procedures
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?